98%
921
2 minutes
20
Patient-reported outcomes measures (PROMs) quantify patients' perspectives about their health and well-being, their functioning (emotional, physical, mental, and social), and their health-related quality-of-life. The Alberta Provincial Project for Outcomes Assessment (APPROACH) developed an ePROM clinical report that includes 4 validated PROM instruments (Seattle Angina Questionnaire, 7-item version [SAQ-7], Patient Health Questionnaire, 2-item and 9-item [PHQ-2 & PHQ-9], Medical Outcomes Study Social Support Survey [MOS SSS], EuroQol Group 5-level assessment [EQ-5D-5L] and the Self-Care of Coronary Heart Disease Inventory). The primary objective of this study is to evaluate the feasibility, acceptability, and efficacy of the APPROACH ePROM clinician report as an adjunct to the care of patients with established coronary artery disease. Utilizing a pre-post interventional study design, we evaluate the APPROACH ePROM tool in 4 outpatient cardiology practices in Alberta over 8 months. A total of 80 patients in the preintervention period and 120 patients in the intervention period will be recruited to participate, and each patient will contribute a single visit. Study outcomes will be evaluated using ePROM usage metrics, and a post-visit survey for both physicians and patients, a single exit interview for physicians, and focus groups for patients. Outcomes will be the feasibility and acceptability of the ePROMs report, as well as its efficacy, based on comparison of measures of physician-patient communication between groups. The pilot will allow us to better understand the possible limitations and facilitators of the study, to guide their further evaluation (full-scale trial) and dissemination. This pilot trial is registered with Clinicaltrials.gov (NCT06164457).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105500 | PMC |
http://dx.doi.org/10.1016/j.cjco.2025.02.009 | DOI Listing |
Ann Am Thorac Soc
September 2025
Brigham and Women's Hospital, Division of Sleep and Circadian Disorders, Boston, Massachusetts, United States.
Rationale: There are insufficient data to inform the management of central sleep apnea (CSA) in patients with heart failure (HF) with reduced ejection fraction (HFrEF). Nocturnal oxygen therapy (NOT) has been postulated to benefit CSA patients with HFrEF, but has not been rigorously studied. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.
View Article and Find Full Text PDFAim To determine the prevalence and predictors for the development of newly diagnosed chronic heart failure (CHF) in patients with shortness of breath in long-term post-COVID syndrome.Material and methods This screening cross-sectional clinical study was performed from April 2020 through April 2024, in two stages in an outpatient setting. At the first stage, 878 patients with shortness of breath were screened three or more months after COVID-19, and the presence of at least three diagnostic criteria for CHF, that were not in their history, was verified.
View Article and Find Full Text PDFDan Med J
August 2025
Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte Hospital.
Introduction: Long-term cardiac monitoring has become more accessible with the advent of consumer-oriented wearable devices. Smartwatches (SWs) hold promise for extended rhythm monitoring owing to their availability and direct electronic health record (EHR) integration. We studied the clinical consequences of SW implementation in patients with palpitations.
View Article and Find Full Text PDFERJ Open Res
September 2025
Department of Bioanalysis, Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Background: In Belgium, age-standardised hospital admission and mortality rates for asthma and COPD are higher than the European average. Understanding the factors that lead to a hospitalised exacerbation and/or mortality is needed to optimise patient management.
Methods: Patients ≥18 years old obtaining two claims for drugs for obstructive airway diseases (ATC code R03) in 1 year between 2017 and 2022 were identified in Belgian nationwide claims-based data.
Eur Heart J Open
September 2025
Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Aims: Pre-clinical studies point towards an administration time-dependency of anthracycline-induced cancer therapy-related cardiac dysfunction (CTRCD). This retrospective study aimed to investigate the association between time-of-day of AC administration and CTRCD.
Methods And Results: Patients from two cardio-oncology outpatient clinics, treated with ACs for any malignancy, were included.